ADAPY — Adaptimmune Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $7.61m
- $7.22m
- $178.03m
- 20
- 53
- 16
- 19
Annual income statement for Adaptimmune Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3.96 | 6.15 | 27.1 | 60.3 | 178 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | — | 178 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 137 | 168 | 191 | 178 | 247 |
| Operating Profit | -133 | -162 | -164 | -118 | -68.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -130 | -157 | -163 | -113 | -67.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -130 | -158 | -165 | -114 | -70.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -130 | -158 | -165 | -114 | -70.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -130 | -158 | -165 | -114 | -70.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.152 | -0.169 | -0.17 | -0.101 | -0.04 |